| Inclusion criteria |
| (1) men and women aged 20 to 80 years |
| (2) patients who have histologically or cytologically confirmed solid tumor |
| (3) patients who are suffering from anorexia |
| (4) patients within 1 month after completion of chemotherapy |
| (5) no plan for additional chemotherapy or radiotherapy |
| (6) anorexia VAS ≥ 40/100 mm |
| (7) Qi deficiency scale ≥ 30 or Blood deficiency scale ≥ 30 |
| (8) neutrophil ≥ 1,500/μl, platelet ≥ 100,000/μl |
| (9) total bilirubin of the maximum normal level or less (1.2 mg/dl) |
| (10) alanine aminotransferase (ALT), aspartate aminotransferase (AST) lower than 2-fold the upper limit of |
| normal |
| (11) creatinine lower than 1.5 fold the upper limit of normal (1.09 mg/dl) |
| (12) written informed consent for participation in the trial |
| Exclusion criteria |
| (1) impossible to intake orally |
| (2) survived at least 5 years after cancer diagnosis |
| (3) Eastern Cooperative Oncology Group (ECOG) performance status score > 3 |
| (4) Patients who have dementia, delirium or depression |
| (5) reports more than 7 points of Numeric Pain Rating Scale |
| (6) Patients who have diseases like hypoadrenalism which can influence on appetite |
| (7) taking palliative medicines such as megestrol acetate, corticosteroids, and thalidomide |
| (8) women of childbearing potential |
| (9) others who are judged not to be appropriate to study |
